A methodologically principled and scientifically responsible process translating data into meaning is the craft of GoodScience.
FRAMEWORK
The GoodScience framework is designed to generate meaningful and reliable evidence from data and support high-quality decisions.
- Underlying causal reality
- Beginning of the data generating process
- Importance of study / experimental design
- Risk of selection bias
- Confounding by indication
- Omitted variables
- Missing data
- Measurement issues
- Information bias
- Model specification
- Model selection
- Assumptions re: distributions
- Model selection
- Model misspecification
- Over-fitting
- Residual confounding
- Arbitrary categorization
- Collider bias
& Belief
- Association vs. Causation
- Cognition / psychology
- Intentions & motivations
& Actions
ETHOS
Any science needs to faithfully connect its observations and measures with a sciences' systematic implications.
Analysis methods are a filter and a lens in the process leading from observations to knowledge and value.
In the communication between the data generating process and knowledge, analysis methods can be low- or high-fidelity. The details of how this connection is performed matter.
All but the most trivial of scientific questions will require modeling. The numerous decisions and assumptions made in the process of regression modeling and estimation determine the accuracy of any signal or pattern that is the target of scientific interest.
Modeling is not simply the plumbing between data and conclusions. Most observational data in health science are generated by largely nonrandom and poorly understood mechanisms of subject selection, exposure assignment, measurement error and missing data; and are analyzed to evaluate effects that are latent under these mechanisms.
Modeling well is a craft: much more than just facility with a toolkit of regression techniques. Rigorous understanding of the specific purposes of the research, the processes that generated the data, the specific analytic strategy and modeling tools employed, and a thorough understanding of the raw material (data and assumptions) that are fed to the model, are all part of a successful program of scientific modeling.
Modeling well begins with asking good questions.
A principled, well integrated and coherent, consistent, and reliable process translating data into meaning is the craft of good science.
PERSPECTIVES
- ODA methods monograph
- HCSRN 2018 ODA Poster
- ODA methods slide presentation
- Graphical Representation of Confounding & Potential for Measured Covariates
- Health Care Entropy and Variation in Practice monograph
- Variation in Practice visual prop'
- VoI and Personalized Medicine.pdf
- VoI ICPE 2014.pdf
- Precision Medicine as VoI, JoPM 2015
- Data Science and Precision Medicine monograph
- Precision Medicine PoV-slide presentation
- HSCRN 2018 abstract LHSvRHS
- HCSRN 2018 abstract ViC.docx
PUBLICATIONS
- Harding CO, Whitehall KB, Lilienstein J, Sazova O, Lindstrom K, Levy DG, Burton BK. Long-term management strategies for pegvaliase use in phenylketonuria: Lessons learned from the phase-3 PRISM open-label extension study. Genet Med. 2025 Aug;27(8):101459.
- Harding CO, Longo N, Northrup H, Sacharow S, Singh R, Thomas JA, Vockley J, Zori RT, Bulloch Whitehall K, Lilienstein J, Lindstrom K, Levy DG, Jones S, Burton BK. Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program. Mol Genet Metab Rep. 2024 Apr 23;39:101084.
- Burton BK, Clague GE, Harding CO, Kucuksayrac E, Levy DG, Lindstrom K, Longo N, Maillot F, Muntau AC, Rutsch F, Zori RT. Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria. Mol Genet Metab. 2024 Jan;141(1):108114.
- Pool JL, Glazer R, Crikelair N, Levy D. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial. Clin Drug Investig. 2009;29(12):791-802.
- Weycker D, Keskinaslan A, Levy DG, Edelsberg J, Kartashov A, Oster G. Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan. Blood Press Suppl. 2008 Dec;2:5-12.
- Black HR, Levy DG, Crikelair N, Rocha R. Predicting age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertens. 2008 Nov-Dec;2(6):476-83.
- Sowers JR, Lastra G, Rocha R, Seifu Y, Crikelair N, Levy DG. Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J Clin Hypertens (Greenwich). 2008 Sep;10(9):668-76.
- Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007 Jul;20(7):807-15.
- Weycker D, Edelsberg J, Vincze G, Levy DG, Kartashov A, Oster G. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother. 2008 Feb;42(2):169-76.
- Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007 Feb;9(2):103-12.
- Levy DG, Stergachis A, McFarland LV, Van Vorst K, Graham DJ, Johnson ES, Park BJ, Shatin D, Clouse JC, Elmer GW. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther. 2000 Jan;22(1):91-102.
- Disch DL, O'Connor GT, Birkmeyer JD, Olmstead EM, Levy DG, Plume SK. Changes in patients undergoing coronary artery bypass grafting: 1987-1990. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 1994 Feb;57(2):416-23.
- O'Connor GT, Morton JR, Diehl MJ, Olmstead EM, Coffin LH, Levy DG, Maloney CT, Plume SK, Nugent W, Malenka DJ, et al. Differences between men and women in-hospital mortality associated with coronary artery bypass graft surgery. The Northern New England Cardiovascular Disease Study Group. Circulation. 1993 Nov;88(5 Pt 1):2104-10.
- Dodds TM, Stone JG, Coromilas J, Weinberger M, Levy DG. Prophylactic nitroglycerin infusion during noncardiac surgery does not reduce perioperative ischemia. Anesth Analg. 1993 Apr;76(4):705-13.
- O'Connor GT, Plume SK, Olmstead EM, Coffin LH, Morton JR, Maloney CT, Nowicki ER, Levy DG, Tryzelaar JF, Hernandez F, et al. Multivariate prediction of in-hospital mortality associated with coronary artery bypass graft surgery. Northern New England Cardiovascular Disease Study Group. Circulation. 1992 Jun;85(6):2110-8.
Drew Levy is the founder of GoodScience, where he focuses on statistical modeling, prediction, causal inference, and evidence quality in healthcare. His work examines how evidence is generated, how signal is distinguished from noise, and how analytic methods support reliable decision-making under uncertainty. He practices the craft of analysis with a principled framework and modern applied methods.